Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.
Let's see what the numbers say about Bristol-Myers Squibb (BMY).
Spectrum, Bristol-Myers Squibb, GSK, and Theravance are the top biotech stocks to watch this morning.
Hepatitis C acquisitions like we've seen from Gilead, Bristol-Myers Squibb, and Merck can't last forever.
Yes, Pfizer should buy Bristol-Myers Squibb instead of AstraZeneca, but it won't.
Big pharma's been in a funk over the recent past with the patent cliff and the recession, but these three stocks have delivered for investors.
BioCryst, Durata, Bristol-Myers Squibb, and Incyte could all loom large in health care headlines today. Here’s why.
How breakthrough designation for a new multiple myeloma drug helps three drug companies.
Check out which stocks one of the world's most successful hedge funds recently bought and why.
Big pharma's home to many great dividends, but is Bristol-Myers Squibb's yield the best bet for your money?